Jiahui Health China Medical Tourism WTO Forum
Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The event highlights a structural growth trend in China's healthcare and medical tourism sector, potentially benefiting hospital operators, insurers offering cross-border coverage, and pharmaceutical firms with China-only innovative therapies. Direct near-term market impact is limited as the forum is promotional and policy-dialogue oriented, but it signals regulatory momentum around visa facilitation and cross-border health data that could expand the addressable market for Chinese healthcare providers.
At the World Trade Organization Public Forum 2026 in Geneva, Dr. John K. Hsiang, Chairman of the Jiahui Health Executive Committee, presented China's expanding role in inbound medical tourism during the Health Without Borders session on Medical Tourism - Opportunities and Challenges in Services Trade. He was the sole Chinese healthcare representative invited to share China's experience in international medical services. According to data cited by Dr. Hsiang, China's leading hospitals serving international patients recorded 1.28 million international patient visits in 2025, up 73.6% from three years earlier, with 413,000 visits by patients who travelled to China specifically for medical care. Jiahui Health saw overseas patient inquiries nearly double year on year in the first half of 2026 and recorded more than 100,000 international outpatient visits in 2025. Growth is supported by China's 240-hour visa-free transit policy covering citizens of 57 countries through 65 ports, and by medical innovation: China now accounts for 33.7% of drugs in global development and in June 2026 approved the world's first CAR-T therapy for a solid tumor. Recent cases include a New Zealand patient with advanced gastric cancer who became the therapy's first international recipient in China — Shanghai, and a U.S. patient with non-small cell lung cancer who came to Jiahui for ivonescimab after discussions with a physician at MD Anderson Cancer Center. Dr. Hsiang positioned China — Shanghai as a gateway connecting Chinese medical innovation with global patients and called for greater international cooperation on medical travel, visa facilitation, information access, and regulatory dialogue on cross-border health data and telemedicine.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard